Noga Or-Geva
9Patents
3h-index
9Co-inventors
46Inventor score
Filing activity: Sep 8, 2011 → Aug 10, 2023
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US9421228B2 | Use of anti third party central memory T cells for anti-leukemia/lymphoma treatment | Chemistry; Metallurgy | 8 | Active |
| US10961504B2 | Veto cells generated from memory T cells | Emerging Cross-Sectional Technologies | 4 | Active |
| US10933124B2 | Methods of transplantation and disease treatment | Emerging Cross-Sectional Technologies | 3 | Active |
| US11179448B2 | Genetically modified anti-third party central memory T cells and use of same in immunotherapy | Emerging Cross-Sectional Technologies | 2 | Active |
| US11844827B2 | Genetically modified anti-third party central memory T cells and use of same in immunotherapy | Emerging Cross-Sectional Technologies | 0 | Active |
| US12133866B2 | Anti third party central memory t cells, methods of producing same and use of same in transplantation and disease treatment | Chemistry; Metallurgy | 0 | Active |
| US12391916B2 | Veto cells generated from memory T cells | Emerging Cross-Sectional Technologies | 0 | Active |
| US11773372B2 | Veto cells generated from memory T cells | Emerging Cross-Sectional Technologies | 0 | Active |
| US11324777B2 | Anti third party central memory T cells, methods of producing same and use of same in transplantation and disease treatment | Chemistry; Metallurgy | 0 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.